Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crizotinib Continuation Study
NCT05160922Phase 4Active, not recruiting
- Sponsor
- Pfizer
- Start
- Dec 2021
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 4 trial of crizotinib in non-small cell lung cancer (NSCLC), anaplastic large cell lymphoma (ALCL), inflammatory myofibroblastic tumor (IMT), sponsored by Pfizer. Started Dec 2021; status: active, not recruiting.
02
Drugs
crizotinib
03
Conditions
non-small cell lung cancer (NSCLC)anaplastic large cell lymphoma (ALCL)inflammatory myofibroblastic tumor (IMT)
Beyond the preview
Go deeper on NCT05160922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05160922.